Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: nonavalent human papillomavirus vaccine Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

NCT06229353
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Gardasil 9
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 6, 2026, 1:08 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Intradermal, Fractional Dose of HPV Vaccines:

NCT04235257
View directory record Official record
Conditions
HPV Infection, HPV Vaccine
Interventions
HPV vaccine
Biological
Lead sponsor
University of Washington
Other
Eligibility
27 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 6, 2026, 1:08 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

NCT04206813
View directory record Official record
Conditions
HPV Infection
Interventions
Gardasil 9 2 dose regimen, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 6, 2026, 1:08 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

NCT05985681
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV16 RG1 VLP Vaccine, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 6, 2026, 1:08 PM EDT
Active, not recruiting Phase 4 Interventional

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03023631
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

NCT05496231
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation, Gardasil 9
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years to 26 Years · Female only
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
39
States / cities
San Diego, California • Wheat Ridge, Colorado • Coral Gables, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

NCT01492582
View directory record Official record
Conditions
Cancer Survivor, Prevention of Human Papillomavirus Infection
Interventions
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration, medical chart review
Biological · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 26 Years
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 6, 2026, 1:08 PM EDT
Terminated Phase 4 Interventional Results available

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

NCT03051516
View directory record Official record
Conditions
High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
27 Years to 69 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 6, 2026, 1:08 PM EDT
Terminated Phase 1 Interventional Results available

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

NCT00798265
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
Interventions
Gardasil, Survey
Biological · Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 26 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 6, 2026, 1:08 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

NCT05266898
View directory record Official record
Conditions
Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Interventions
Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 6, 2026, 1:08 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

NCT02568566
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
9 Years to 11 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
2
States / cities
Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 6, 2026, 1:08 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

NCT07493460
View directory record Official record
Conditions
Immunology, Healthy Adults
Interventions
trivalent inactivated influenza vaccine (TIV), nonavalent HPV vaccine (HPV), hepatitis A (HAV) vaccines, tetanus, diphtheria and acellular pertussis vaccine (Tdap)
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 6, 2026, 1:08 PM EDT
Recruiting Phase 2Phase 3 Interventional

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

NCT05625633
View directory record Official record
Conditions
Warts
Interventions
Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline
Biological · Other
Lead sponsor
Western Institute for Veterans Research
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intralesional HPV Vaccine for Condylomata

NCT05087849
View directory record Official record
Conditions
Human Papilloma Virus, Warts, Warts, Genital, Condyloma, Condylomata Acuminata
Interventions
nonavalent human papillomavirus vaccine
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 6, 2026, 1:08 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Fractional Dose of the HPV Vaccines

NCT05291871
View directory record Official record
Conditions
HPV Infection, HPV Vaccine
Interventions
HPV vaccine
Biological
Lead sponsor
University of Washington
Other
Eligibility
27 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 6, 2026, 1:08 PM EDT
Active, not recruiting Phase 4 Interventional

Immunogenicity of HPV Vaccine in Transplant Recipients.

NCT05557370
View directory record Official record
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Human Papilloma Virus vaccine (GARDASIL 9)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 6, 2026, 1:08 PM EDT
Active, not recruiting Phase 2 Interventional

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

NCT03519464
View directory record Official record
Conditions
Idiopathic CD4 T Cell Lymphocytopenia
Interventions
Gardasil 9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 6, 2026, 1:08 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

NCT03036930
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 6, 2026, 1:08 PM EDT